biostudies-literatureRajasekhar MWellcome TrustIntramural CDC HHS184-195https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615565biostudies-literatureUnknown24(2)<h4>Background</h4>Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaquThe Lancet. Infectious diseasesPrimaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.PMC7615565CC999999093956/Z/10/Z200909093956/Z/10/C223253/Z/21/ZGreen JAChau NHRijal KRSaravu KKarunajeewa HBancone Gvon Seidlein LAdhikari BPrice RNNaadim MNTaylor WRJBoyd SCGhimire PLadeia-Andrade SBaird JKDegaga TSNosten FKhan WAAbreha TAnstey NMAwab GRWatson JAChu CSGuerin PJWoyessa AAssefa AWorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study GroupSimpson JABarber BEGrigg MJLlanos-Cuentas AKoh GCFerreira MUDondorp AMAlam MSThriemer KCommons RJWilliam THwang JLacerda MVGPasaribu APPrice DJDay NPRajasekhar MWoodrow CJSutanto IMekuria AHPukrittayakamee SLey BNelwan EJEdler PStepniewska KWhite NJfalsePrimaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.<h4>Background</h4>Primaquine radical cure is used to treat dormant liver-stage parasites and prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We undertook a systematic review and individual patient data meta-analysis to investigate the haematological safety of different primaquine regimens for P vivax radical cure.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, if they included a treatment group with daily primaquine given over multiple days where primaqu2024-01-01T00:00:00Z2024 Feb2026-07-15T02:35:58.694Z2026-06-28T03:07:36.6ZS-EPMC76155653774849710.1016/S1473-3099(23)00431-0